
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX is a promising epigenetics company that uses its Nucleosomics platform to develop easy-to-use, cost-effective blood tests for diagnosing and monitoring diseases such as cancer and conditions associated with NETosis. The company's current positive cash position indicates enough capital to sustain operations until the mid-2026, but potential for future growth and revenue generation will depend on successful validation and adoption of their tests in clinical settings. The company's partnerships, regulatory progress, and evidence-based publications will be important catalysts to watch for in the near future to assess their potential impact on market adoption and financial success.
Bears say
VolitionRX is facing multiple risk factors related to its clinical and regulatory compliance, potential partnerships, commercialization, legal and intellectual property issues, and market share. The recent reverse stock split, ongoing platform validation, and lack of tangible commercial traction are key near-term catalysts that may impact investor sentiment. The company's financial results for 2025 showed lower than expected revenue and higher net loss, while discussions with potential licensing partners may drive future revenue growth. However, the company will likely need time to rebuild credibility with the market and address concerns about potential dilution or balance sheet actions.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares